U.S. FDA moving with ‘lightning speed’ on Gilead’s COVID-19 drug – Bloomberg

FILE PHOTO: A lab technician loads bright stock filled vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, U.S. March 11, 2020. Gilead Sciences Inc/Handout via REUTERS

(Reuters) – The U.S. Food and Drug Administration is working at “lightning speed” to review data on Gilead Sciences Inc’s (GILD.O) experimental antiviral drug remdesivir in treating COVID-19 disease, the head of the agency told Bloomberg in an interview.

“We’re working with the company to emphasize the necessity of speed while at the same time to understand the data,” FDA Commissioner Stephen Hahn said.

Meanwhile, the FDA in an email statement to Reuters, reiterated it was in talks with Gilead about making the drug available to patients as quickly as possible.

Anthony Fauci, the top U.S. infectious disease official, had said on Wednesday remdesivir will become the standard of care for COVID-19 after early clinical trial results showed it helped patients recover more quickly from the illness caused by the coronavirus.

Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur

Source Article

Next Post

Millions of Americans continue to seek jobless benefits; consumer spending tanks

WASHINGTON (Reuters) – Millions more Americans filed claims for unemployment benefits last week, suggesting that layoffs were spreading to industries that were not initially directly impacted by business closures and disruptions related to the coronavirus. Other data on Thursday showed a record collapse in consumer spending in March as the […]